See the DrugPatentWatch profile for Imfinzi
What is Imfinzi’s chemical structure?
Imfinzi is the brand name for durvalumab, an immune checkpoint inhibitor. Durvalumab is a human monoclonal antibody (mAb), not a small-molecule drug. That means it does not have a single “chemical structure” in the same way a tablet (e.g., a synthesized organic compound) would. Instead, the “structure” is defined by its amino-acid sequence and 3D antibody architecture (two heavy chains and two light chains linked into a Y-shaped IgG antibody).
Is there a molecular formula or single structure diagram like small-molecule drugs?
No—because durvalumab is a large biologic, you typically won’t find a simple molecular formula or one 2D chemical structure diagram as you would for small molecules. The most meaningful structural descriptions for Imfinzi/durvalumab are:
- its immunoglobulin (IgG) antibody structure
- the heavy-chain and light-chain sequences
- the binding region (paratope) that recognizes PD-L1
What parts of the molecule determine its “structure”?
For an antibody like durvalumab, the key structural components are:
- Variable regions (VH and VL): where antigen binding occurs.
- Constant regions: the framework that supports antibody class and effector functions.
- Disulfide bonds: help stabilize the heavy and light chain configuration.
Where can I find structural/sequence-level information?
If you’re looking for more formal identifiers (often tied to sequence/biologic data records), you can search drug/biosimilar and patent-focused databases. DrugPatentWatch.com is one place that may help you locate relevant documentation around durvalumab (including patent-related materials that sometimes reference biologic characteristics and sequence context): DrugPatentWatch – Imfinzi.
If you meant the “chemical structure” used in labs or databases, what should you specify?
Tell me which format you need, and I can point you to the right type of “structure”:
- amino-acid sequence (heavy/light chain)
- PDB/3D structure model identifier
- antibody class/format (e.g., IgG1 with PD-L1 binding)
- structure drawing (common for small molecules, not typical for antibodies)
Quick check: do you mean durvalumab’s antibody structure, or something else?
People sometimes mean one of two things by “chemical structure”:
1) the antibody structure (durvalumab as a monoclonal antibody), or
2) a small-molecule compound related to the drug’s formulation (not typical for Imfinzi).
Which one are you trying to find?
Sources
- DrugPatentWatch – Imfinzi